Idea principal
In a network meta-analysis of 61 randomized trials with 4,744 participants, whole soy ranked best for lowering fasting glucose (SUCRA 91.0%), fasting insulin (95.4%) and HOMA-IR (83.4%), with isolated isoflavones next, while no soy product changed HbA1c. Rankings show relative order only and do not give the size of benefit.
Study design
Metaanálisis de ensayos
Reading basis
Published abstract
Reading focus
Design & applicability
Esta explicación editorial está disponible en inglés, chino simplificado y chino tradicional. Esta interfaz muestra la lectura en inglés.
Pregunta de investigación
Soy foods and soy extracts may help blood sugar control, but soy comes in several forms and it is unclear which works best. The authors compared and ranked whole soy, soy extracts and related products for effects on glucose control and insulin sensitivity.
Población y método
Network meta-analysis of randomized controlled trials found by searching PubMed, Embase and the Cochrane Library; 61 trials with 4,744 participants were included. The authors used random-effects models, ranked soy types by the surface under the cumulative ranking curve (SUCRA, where higher means more likely to be best), and ran sensitivity analyses for possible sources of heterogeneity. Outcomes were fasting glucose, fasting insulin, HOMA-IR (an insulin resistance index) and HbA1c. The protocol was registered in PROSPERO (CRD42022345831).
Resultados
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1Fasting glucose: whole soy ranked first (SUCRA 91.0%) and isolated isoflavones second (79.1%).
- 2Fasting insulin: whole soy ranked first (95.4%) and isolated isoflavones second (74.7%).
- 3HOMA-IR: whole soy (83.4%) and soy protein plus isoflavones (83.3%) ranked highest.
- 4No soy product had a significant effect on HbA1c, the measure of average glucose over about 3 months.
Límites e incertidumbre
- 1SUCRA values rank treatments against each other; the abstract does not give mean differences or confidence intervals, so the size of the improvement is unknown.
- 2The abstract does not say which participants had diabetes or what the trial durations and doses were, so results may differ by group.
- 3The authors flag heterogeneity between trials and ran sensitivity analyses, but their results are not reported in the abstract.
- 4Rankings can look decisive when the underlying evidence is thin; based on the abstract only.
Relevancia práctica
Soy foods may modestly help fasting glucose and insulin, but the lack of any effect on HbA1c suggests the long-run benefit is uncertain. Treat it as one dietary option, not a replacement for diabetes care, and check with your clinician before changing a diabetes diet.
Tus datos
If you track fasting glucose or a CGM, compare weeks before and after adding soy foods under similar meals, sleep and activity, and expect small changes at best. HbA1c comes from lab tests every few months, not daily tracking.
Cómo interpretar la evidencia
Pooling trials can improve precision, but compare populations, controls, bias and uncertainty. Network rankings include indirect evidence and do not identify a universal best treatment.
Resumen estructurado de los autores English
El resumen original en inglés se reproduce con atribución bajo la licencia indicada. Es una fuente, no una interpretación de MoveVitals. El análisis preparado figura arriba; verifica los resultados importantes en la fuente.
Background and aims
Accumulating evidence has demonstrated the benefits of soy and its extracts on glycemic control and insulin sensitivity. We hypothesized that different soy components might exhibit differentiated blood glucose and insulin sensitivity regulation effects. The goal of this network meta-analysis of randomized clinical trials (RCTs) was to estimate and rank the relative effects of soy and its extracts on glycemic control and insulin sensitivity.
Methods
We performed a strategic literature search of PubMed, Embase, and the Cochrane Library for relevant RCTs. Random-effects network meta-analyses, ranking analyses based on surface under the cumulative ranking curves (SUCRAs), and sensitivity analyses based on potential sources of heterogeneity were performed. We registered the study protocol at PROSPERO (no. CRD42022345831).
Results
Sixty-one RCTs enrolling 4,744 participants were included in the quantitative analysis. In random-effects network meta-analyses. Whole soy was ranked as the best diet (SUCRA: 91.0%) regarding fasting glucose-lowering effects, with isolated isoflavones was ranked as second (SUCRA: 79.1%). For fasting insulin regulation, the best soy component choices was whole soy (SUCRA: 95.4%) and isolated isoflavones (SUCRA: 74.7%). For HOMA-IR regulation, the best soy component choices was whole soy (SUCRA: 83.4%) and Soy protein + isoflavones (SUCRA: 83.3%). No soy products showed significant effect on regulating glycated HbA1c.
Conclusions
These findings highlight that different soy components exhibit distinct effects on regulating blood glucose and insulin sensitivity. In this network meta-analysis, whole soy and isolated isoflavones were identified as potentially superior choices for improving blood glucose control and insulin sensitivity compared with other soy products.
Systematic review registration
http://www.crd.york.ac.uk/ PROERO, identifier CRD42022345831.
Fuentes y atribución
Comparative effects of different types of soy products on glycemic control and insulin sensitivity: a network meta-analysis of randomized controlled trials.
Luo Q, Kang B, Lei L, Yan H, Chen M, Peng T, Ouyang Y, Sun H, Hui S.
Frontiers in nutrition · 2026-01-20
DOI: 10.3389/fnut.2025.1681229 ↗PubMed · 41640735 ↗Europe PMC · Licencia registrada: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
Interpretación editorial de MoveVitals · contenido educativo · sin revisión clínica individual registrada
Fuentes verificadas 2026-11-01
Guías prácticas
Leer en contexto
Early time-restricted eating linked to more weight loss and lower insulin than late eating
Pooling 41 randomised trials (2287 participants, median intervention 8 weeks), time-restricted eating was associated with 2.15 kg lower body weight than usual diets (95% CI -2.56 to -1.74), and eating early beat eating late by 1.15 kg (95% CI -1.86 to -0.45). Most trials were short, only 6 study arms tested early eating, and the outcomes were body and blood measures, not heart attacks or deaths.
BMJ Medicine
An 8 a.m. to 4 p.m. eating window added to calorie cutting gave no clear extra weight loss
Among 139 patients with obesity on a calorie-restricted diet, adding an eating window of 8:00 a.m. to 4:00 p.m. led to a mean 12-month weight change of -8.0 kg, versus -6.3 kg with calorie restriction alone. The net difference of -1.8 kg (95% CI -4.0 to 0.4; P = 0.11) was not statistically significant, and the interval cannot rule out either a real benefit or none.
The New England Journal of Medicine
In a 20-person ward trial, an ultra-processed menu led to more eating and weight gain
In 20 adults living in a hospital research unit for 28 days, an ultra-processed menu led them to eat 508 kcal/day more (± 106 SE, P = 0.0001) and gain 0.9 kg, while a menu of unprocessed foods led to a 0.9 kg loss, each over 2 weeks and with eating left to appetite. The study was small, short and fully provisioned, so it cannot show what happens in daily life or which feature of the foods drove the extra eating.
Cell Metabolism
Mediterranean diet with olive oil or nuts linked to fewer heart events (corrected trial)
Among 7447 Spanish adults aged 55 to 80 at high cardiovascular risk, those assigned to a Mediterranean diet with extra-virgin olive oil (HR 0.69, 95% CI 0.53 to 0.91) or with nuts (HR 0.72, 0.54 to 0.95) had fewer major cardiovascular events than those told to cut dietary fat. The trial had randomisation errors, which is why the 2013 report was withdrawn and the estimates recalculated, so treat this as strong but imperfect evidence.
The New England Journal of Medicine

